EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF^V600E mutation: a case report and review of literature

Abstract

Despite the promising initial anti-tumor efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), most advanced non-small-cell lung cancers (NSCLCs) progress eventually due to therapeutic resistance. V-Raf murine sarcoma viral oncogene homolog B1 (BRAF)^V600E mutation has been considered as an uncommon mutation that contributes to acquired resistance for EGFR-TKIs. In the presented case, BRAF^V600E mutation was detected as an acquired resistance-mediated mutation in a patient treated with osimertinib (a third-generation EGFR-TKI). The presented patient achieved partial regression and ongoing PFS of four months after the co-inhibition of osimertinib plus dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor). Our case further enriches the clinical evidence of the efficacy of EGFR/BRAF/MEK co-inhibition in patients with an acquired BRAF^V600E mutation, consistent with the review of the literature (eight cases). Additionally, our case highlights the important role of sample type, method, and platform of gene detection in patient management, life quality, and prognosis, as well as the understanding of acquired resistance mechanism.

Keywords

NSCLC / targeted therapy / resistance mechanisms / EGFR mutation / BRAF^V600E mutation / case report

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] Rosell R,Queralt C.Spanish Lung Cancer GroupScreening for epidermal growth factor receptor mutations in lung cancer.N Engl J Med2009;361:958-67

[3] Shi Y,Thongprasert S.A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).J Thorac Oncol2014;9:154-62 PMCID:PMC4132036

[4] Recondo G,Olaussen KA,Friboulet L.Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?.Nat Rev Clin Oncol2018;15:694-708

[5] Rotow J.Understanding and targeting resistance mechanisms in NSCLC.Nat Rev Cancer2017;17:637-58

[6] Ohashi K,Arcila ME.Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.Proc Natl Acad Sci U S A2012;109:E2127-33 PMCID:PMC3411967

[7] Davies H,Cox C.Mutations of the BRAF gene in human cancer.Nature2002;417:949-54

[8] Subbiah V,Kirkwood JM.Clinical development of BRAF plus MEK inhibitor combinations.Trends Cancer2020;6:797-810

[9] Yao Z,Tao A.BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition.Cancer Cell2015;28:370-83 PMCID:PMC4894664

[10] Oxnard GR,Mileham KF.Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib.JAMA Oncol2018;4:1527-34 PMCID:PMC6240476

[11] Leonetti A,Minari R,Giovannetti E.Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.Br J Cancer2019;121:725-37 PMCID:PMC6889286

[12] Ho CC,Lin CA,Yu CJ.Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib.J Thorac Oncol2017;12:567-72

[13] Huang Y,Guo K,Fang W.Acquired BRAF V600E mutation mediated resistance to osimertinib and responded to osimertinib, dabrafenib, and trametinib combination therapy.J Thorac Oncol2019;14:e236-7

[14] Mauclet C,Ghaye B,Nana FA.Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAF^V600 mutation as an acquired resistance mechanism.Lung Cancer2021;159:42-4

[15] Solassol J,Senal R,Leenhardt F.Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.Lung Cancer2019;133:45-7

[16] Zhou F,Chen X,Zhou C.Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF^V600E mutation.Lung Cancer2020;139:219-20

[17] Meng P,Kok K.Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.Lung Cancer2020;146:358-61

[18] Ribeiro MFSA,Bettoni F.Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.NPJ Precis Oncol2021;5:5 PMCID:PMC7880994

[19] Ding H,Xie J,Tao Z.Durable clinical response of advanced lung adenocarcinoma harboring EGFR-19del/T790M/BRAF^V600E mutations after treating with osimertinib and dabrafenib plus trametinib: a case report.Onco Targets Ther2020;13:7933-9 PMCID:PMC7428409

[20] US Department of Health and Human Services. Common Terminology criteria for adverse events. Version 5.0. Published November 27, 2017. (2020).

[21] Mu Y,Hao X.Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated non-small cell lung cancer.Front Oncol2020;10:603 PMCID:PMC7198730

[22] Planchard D,Groen HJM.Dabrafenib plus trametinib in patients with previously treated BRAF^V600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Lancet Oncol2016;17:984-93

[23] Planchard D,Groen HJM.Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis.J Thorac Oncol2021;S1556-0864(21)02403:

[24] Schadendorf D,Dummer R.Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.Eur J Cancer2021;153:234-41

[25] Barlesi F,Merlio J.Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).Lancet2016;387:1415-26

[26] Dudnik E,Nechushtan H.Israel Lung Cancer GroupBRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors.J Thorac Oncol2018;13:1128-37

[27] Zhang C,Lin J,Wang H.Patients with BRAF-mutant NSCLC may not benefit from immune checkpoint inhibitors: a population-based study.JTO Clin Res Rep2020;1:100006

[28] Mazieres J,Lusque A.Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.Ann Oncol2019;30:1321-8 PMCID:PMC7389252

[29] Jóri B,Kaller L.Comparison of resistance spectra after first and second line osimertinib treatment detected by liquid biopsy.Cancers (Basel)2021;13:2861 PMCID:PMC8227553

[30] Nichols D,Noyes D.Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis.J Thorac Dis2018;10:6254-60 PMCID:PMC6297393

[31] de Miranda FS, Barauna VG, Dos Santos L, Costa G, Vassallo PF, Campos LCG. Properties and application of cell-free DNA as a clinical biomarker.Int J Mol Sci2021;22:9110 PMCID:PMC8431421

[32] Arrieta O,Cardona AF.Association of carcinoembryonic antigen reduction with progression-free and overall survival improvement in advanced non-small-cell lung cancer.Clin Lung Cancer2021;22:510-22